Cytokinetics (NASDAQ:CYTK) Announces Quarterly Earnings Results

Cytokinetics (NASDAQ:CYTK) released its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($1.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.43) by $0.06, Zacks reports. The firm had revenue of $47.56 million for the quarter, compared to analysts’ expectations of $41.88 million. During the same quarter in the prior year, the business earned ($2.55) EPS. The company’s quarterly revenue was up 2356.5% compared to the same quarter last year.

Here are the key takeaways from Cytokinetics’ conference call:

• MYQORZO generated $44.5 million in Q3 net product revenue, up 76% sequentially. Prescribers and dispensed patients grew, while new-to-brand share approached 45%; the company is targeting more than 50% by year-end.
• Cytokinetics plans to submit an aficamten supplemental NDA for symptomatic non-obstructive HCM this quarter, following positive Phase 3 ACACIA-HCM results. The company is also preparing for a potential 2027 launch, though approval and the eventual label remain uncertain.
• MYQORZO’s international rollout is progressing, with Germany showing early traction and a U.K. launch expected this quarter. The company expects launches in additional countries in 2027, while noting broader European revenue may take until 2028–2029 to build meaningfully.
• The company ended Q3 with approximately $1.6 billion in cash and investments and reaffirmed 2026 combined R&D and SG&A expense guidance of $860 million–$890 million. Quarterly SG&A increased to $113.1 million as commercial launch costs rose, while the company reported a $190.1 million net loss.

Cytokinetics Price Performance

Shares of NASDAQ CYTK traded down $0.74 during trading on Friday, hitting $54.81. 1,253,439 shares of the company were exchanged, compared to its average volume of 2,110,190. The company has a market cap of $6.82 billion, a price-to-earnings ratio of -9.08 and a beta of 0.45. Cytokinetics has a 1 year low of $54.16 and a 1 year high of $88.31. The firm’s fifty day moving average price is $66.16 and its 200 day moving average price is $70.02.

Insider Activity at Cytokinetics

In related news, EVP Andrew Callos sold 10,000 shares of the business’s stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $70.24, for a total transaction of $702,400.00. Following the sale, the executive vice president owned 58,555 shares of the company’s stock, valued at approximately $4,112,903.20. The trade was a 14.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Fady Malik sold 3,500 shares of the company’s stock in a transaction dated Tuesday, September 22nd. The stock was sold at an average price of $68.29, for a total transaction of $239,015.00. Following the transaction, the executive vice president owned 153,902 shares in the company, valued at $10,509,967.58. The trade was a 2.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 180,926 shares of company stock valued at $12,510,340. Company insiders own 2.60% of the company’s stock.

Trending Headlines about Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: For Q3 2026, Cytokinetics reported a loss of $1.37 per share, narrower than analysts’ expected $1.43 loss, and revenue of $47.56 million versus estimates of $41.88 million. Revenue rose sharply year over year, while the loss per share narrowed from $2.55. The results could support investor confidence in the company’s commercial progress. Cytokinetics Q3 Loss Narrows, Revenue Rises
• Positive Sentiment: Analysts reiterated a constructive outlook: Citigroup raised its target to $105 and kept a Buy rating, while Morgan Stanley also issued a Buy rating. Leerink Partners’ new $100 target was accompanied by an Outperform rating. Citigroup price-target update Morgan Stanley Buy rating
• Positive Sentiment: RBC Capital Markets said MYQORZO could drive a revenue inflection beginning in 2027, highlighting the drug’s potential contribution to future growth. RBC on MYQORZO revenue potential
• Negative Sentiment: Leerink Partners trimmed its price target from $103 to $100. The cut was limited, and the firm retained its Outperform rating. Leerink Partners price-target update

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on CYTK. JPMorgan Chase & Co. upped their target price on shares of Cytokinetics from $97.00 to $103.00 and gave the company an “overweight” rating in a report on Thursday, August 13th. UBS Group reaffirmed a “buy” rating and set a $104.00 price objective on shares of Cytokinetics in a research note on Wednesday, October 14th. Truist Financial increased their price objective on Cytokinetics from $106.00 to $112.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Needham & Company LLC increased their price target on Cytokinetics from $102.00 to $112.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Finally, Royal Bank Of Canada lifted their price objective on shares of Cytokinetics from $112.00 to $113.00 and gave the company an “outperform” rating in a research report on Thursday, October 8th. Nineteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $106.67.

About Cytokinetics

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that target muscle function and contractility. The company applies muscle biology and sarcomere science to develop potential treatments for cardiovascular and neuromuscular diseases, including conditions in which impaired muscle performance contributes to disease progression.

Its leading investigational program is aficamten, a selective cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy and other potential cardiovascular indications.